Evaluation of primary outcome (therapeutic efficacy)
rash
Although no significant difference existed between both groups as regards therapeutic efficacy, the percent reduction in the extent of the rash as a whole and the extent of the hypopigmented lesions were significantly more in the NB-UVB group compared to the azithromycin group (Results of the RCTExtent of erythematous papules at EOS(% body surface) (mean ± SD)*